Kidneys work quietly in the background, filtering waste, balancing fluids, and maintaining chemical stability without demanding attention. But this is until som ...

In unadjusted analysis, rates of DKA among individuals with an eGFR between 30 and 90 mL/min/1.73 m 2 showed no statistical difference compared with those with an eGFR between 90 and 120 mL/min/1.73 m ...

Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive ...

PBS293-MMAE targets EGFR and EphA2, two proteins shown to be co-expressed in colorectal cancer cells. While EGFR is a clinically validated target in colorectal cancer, therapeutic antibodies such as ...

A proposed function of TADs is to contribute to gene regulation by promoting chromatin interactions within a TAD and by suppressing interactions between TADs. Here, we directly probe the ...

Kidney problems never or rarely announce themselves loudly. There is no sudden pain or obvious warning in the early stages, ...

Japan: A fixed-dose combination of anagliptin and metformin appears to be safe for patients with type 2 diabetes mellitus (T2DM) who also have moderate renal impairment, according to findings ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...

Results show that it may be beneficial to add longitudinal monitoring of kidney function to the management of patients with MDS.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...